FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

		•	

	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Name and Address of Reporting Person* Peoples Oliver P						2. Issuer Name and Ticker or Trading Symbol YIELD10 BIOSCIENCE, INC. [YTEN]									5. Relationship of Reportin (Check all applicable) X Director		le)	10% Owner	
(Last) (First) (Middle) C/O YIELD10 BIOSCIENCE, INC. 19 PRESIDENTIAL WAY						3. Date of Earliest Transaction (Month/Day/Year) 09/03/2019										Officer (give title below) Pres & CEO Other (spec below)			
(Street) WOBURN MA 01801 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									ine) X I				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,					Securities Acquired (A) o sposed Of (D) (Instr. 3, 4					.	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount (A) or D)	Price	_ Tr	nsaction str. 3 and			(instr. 4)	
Common Stock 09/03/2					/2019	019		P		10,000(1)		Α	\$0.8	32 ⁽²⁾	57,628		D		
Common Stock															18,246 ⁽³⁾		I	By 401(k) Plan	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) of Disp of (D) (Instr	rities ired r osed) : 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date		e (ar)	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		ount nber	Derivat Securit	8. Price of Derivative Security (Instr. 5) (Instr. 5) (Instr. 5) (Instr. 5) (Instr. 4) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. These shares were purchased pursuant to a Rule 10b5-1 buying plan adopted by the reporting person on June 3, 2019.
- 2. Represents the weighted average sales price for the shares purchased. Sales prices for this transaction ranged from \$0.7945 to \$0.8300. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, Yield10 Bioscience, Inc., or a security holder of Yield10 Bioscience, Inc., full information regarding the number of shares purchased at each separate price.
- 3. These shares were acquired as Company matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.

/s/ Megan N. Gates, attorneyin-fact 09/04/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.